Table 3.
Effectiveness of IG SC in preventing infections/efficacy of IG SC – clinical trials
| Year | Location | N | Mean dose (mg/kg/week) | Mean IgG | SBI annual rate | Other infection | Hospital days* | Missed days* | Antibiotic days* |
|---|---|---|---|---|---|---|---|---|---|
| 200622 | EU | 52 | 100 | 922 | 0.04 | 4.3 | 12/1 | NR | NR |
| 200621 | US | 51 | 158 | 1040 | 0.04 | 4.4 | 0.23 | 3.7 | 120.2 |
| 201037 | US | 51 | NR | 1100 | 0.03 | 3.4 | 4d (1) | 4.5 | NR |
| 201020 | US | 32 | 1.37x IVIG dose |
1140 | 0 | 4.1 | NR | NR | NR |
| 201038 | US | 38 | 1.53x IVIG dose |
1250 | 0 | 2.8 | 0.2 | 2.1 | 48.5 |
| 201140 | US | 47 | 182.6 | 1202 | 0.067 | 4.1 | 0 | 4 | 37.3 |
| 201139 | EU | 46 | 118.5 | 810 | 0 | 5.2 | 0.95 | 5.2 | 66.6 |
| 201119 | EU | 18 | 129.9 (children) | 778 | 0 | 4.8 | 1.7 | 7.7 | 30.6 |
| 5 | 113.7 (teens) | 814 | 0 | 5.2 | 0 | 1.8 | 0.4 | ||
| 28 | 114.3 (adults) | 832 | 0 | 5.5 | 0.63 | 4.3 | 59.4 |
Note:
*
Days per subject per year.
Abbreviations: N, number of subjects; NR, not reported; IG, immunoglobulin; SC, subcutaneous, IVIG, intravenous immunoglobulin.